Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. PharmaCielo Ltd.
  6. News
  7. Summary
    PCLO   CA71716K1012


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PharmaCielo : to Participate in the Cantor Fitzgerald International Cannabis Forum

06/23/2021 | 06:31am EDT

TORONTO and RIONEGRO, Colombia, June 23, 2021 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that Henning von Koss, Chief Executive Officer will participate in a discussion at the Cantor Fitzgerald International Cannabis Forum on June 28, 2021.


Date: Monday, June 28, 2021.

Time: 12:00pm ET

To Register: https://us06web.zoom.us/webinar/register/WN_HMS7kf5zQEOpc1drtylmzA

To receive additional information or schedule a one-on-one meeting with management, please contact your conference representative or the Company's investor relations team at investors@pharmacielo.com.

About PharmaCielo

PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its cultivation and processing centre located in Rionegro, Colombia.

The board of directors and executive team of PharmaCielo are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location and climate play in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.

Forward-Looking Statements

This news release contains certain "forward-looking information" and "forward-looking statements" (collectively referred to as "forward-looking statements"). These forward-looking statements relate to future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Particularly, information regarding our expectations of future results, targets, performance achievements, prospects or opportunities is forward-looking information.

Forward-looking statements are based on management's assumptions at the date the forward-looking statements are provided, including assumptions regarding: the Company's ability to execute its business plan, including the growth of its global sales team, as currently contemplated; the Company's ability to obtain necessary governmental, regulatory, and TSXV approvals for the export of its products from Colombia and import of its products into other countries; there being sufficient demand for the Company's products; that the Company's development plans will not change as a result of unforeseen events; that the Company's business generally and shipping logistics are not disrupted by COVID 19 or other factors; that the Company will be able to maintain its customer contracts in good standing; that the Company will be able to obtain GMP and EU-GMP certification for the Company's Processing and Extraction Center ("PEC"); that potential customers will be satisfied with the results of audit processes; that any changes to Colombian cannabis legislation will not negatively impact the Company's business; that the Company will be able to locate and retain necessary personnel to achieve its business goals; the Company's ability to maintain its distribution contracts in good standing; and the accuracy of the Company's projections regarding the market for cannabinoid products; currency exchange rates; and competition in the Company's markets.

Though management believes that its assumptions are reasonable in the circumstances, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to differ materially from all or any of the future results, performance or achievements expressed or implied by forward-looking statements. Factors that could cause the Company's actual results, performance, or achievements to differ from the forward-looking statements include, but may not be limited to the risk that: any of the assumptions referred to above proves not to be valid or reliable, and additional risks described in the Company's Annual Information Form for the year ended December 31, 2019 filed with the Canadian securities regulatory authorities under the Company's SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on forward-looking statements.

Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PharmaCielo Ltd.

© Canada Newswire, source Canada Newswire English

All news about PHARMACIELO LTD.
09/14PHARMACIELO : Receives Confirmation of Colombian Phytotherapeutics GMP Certifica..
09/01PHARMACIELO : Announces the Appointment of Cannabis Industry Veterans Bob DeGabr..
09/01PharmaCielo Ltd. Announces Board Appointments
08/20PHARMACIELO : Says its Second-Quarter Loss Widens as Sales Plunge; CEO Departs
08/20Pharmacielo Ltd. Announces CEO Changes
08/20PharmaCielo Ltd. Announces Earnings Results for the Six Months Ended June 30,..
08/20Pharmacielo Ltd. Provides Revenue Guidance for the Second Half of 2021
08/20PHARMACIELO : Announces Q2-2021 Financial Results and Appointment of Bill Petron..
08/20PharmaCielo Ltd. Announces Resignation of Henning Von Koss as Director
08/04PHARMACIELO : Signs Sales Agreement and Makes Initial Commercial Sale to Pharmac..
More news
Sales 2021 4,04 M 3,14 M 3,14 M
Net income 2021 -20,5 M -16,0 M -16,0 M
Net Debt 2021 - - -
P/E ratio 2021 -9,46x
Yield 2021 -
Capitalization 183 M 143 M 142 M
Capi. / Sales 2021 45,3x
Capi. / Sales 2022 7,40x
Nbr of Employees -
Free-Float 96,9%
Duration : Period :
PharmaCielo Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARMACIELO LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,23 CAD
Average target price 2,38 CAD
Spread / Average Target 93,1%
EPS Revisions
Managers and Directors
Bill Petron Chairman & Chief Executive Officer
Ian D. Atacan Chief Financial Officer
Matteo Lorenzo Pellegrini Independent Director
Douglas H. Bache Independent Director
Claudia Jimenez Jaramillo Director
Sector and Competitors
1st jan.Capi. (M$)
DONG-E-E-JIAO CO.,LTD.-15.86%3 244
CRONOS GROUP INC.-14.14%2 222